Researchers have developed a new compound that can prevent long COVID symptoms in mice that could lead to a future drug for the debilitating condition in humans. Developed by researchers at the Walter and Eliza Hall Institute of Medical Research (WEHI) in Melbourne, the world-first study found mice treated with the antiviral compound were protected from long-term brain and lung dysfunction, which are key symptoms of long COVID. Read More
In a roadmap to change animal testing requirements for INDs, the U.S. FDA said its new approach will improve drug safety, hasten the evaluation process, and lower costs for companies and patients. It’s another step in a process of changing rules put in place decades ago. Read More
CSPC Pharmaceutical Group Ltd. has obtained clinical trial approval from China’s National Medical Products Administration (NMPA) for SYH-2046 for heart failure after acute myocardial infarction. Read More
The specific tau isoforms, such as 3-repeat (3R) and 4-repeat (4R) isoforms, and the distinct conformational strains that misfolded tau can adopt are determinants of the molecular and clinical heterogeneity observed across tauopathies. Read More
Cutaneous melanoma nearly always arises on parts of the body that receive abundant sun but, rarely, it can arise on parts that do not, such as the palms of the hands or soles of the feet. These rare cases of acral and mucosal melanomas, which often feature mutations in the transmembrane tyrosine kinase KIT, do not respond to current melanoma therapies. Read More
Nipah virus, which circulates in fruit bats and other animals primarily in Asia and the South Pacific, causes severe neurological respiratory disease in humans and leads to death in 40%-75% of cases. The virus is endemic in Bangladesh and India, where outbreaks have occurred nearly annually since 2001. Read More
Erasmus Universitair Medisch Centrum Rotterdam has disclosed drug conjugates consisting of a 1,3,5-triazine core or a 1,3,5-triazinane core that is connected to two FAP-binding moieties via linkers and to a payload via another linker reported to be useful for the diagnosis and treatment of cancer. Read More
Researchers from China Pharmaceutical University and Jiangsu Nhwa Pharmaceutical Co. Ltd. have synthesized azetidine-containing compounds acting as muscarinic M4 receptor positive allosteric modulators (PAMs) reported to be useful for the treatment of Alzheimer’s disease, asthma, pain, schizophrenia, pulmonary hypertension, Huntington’s disease, Parkinson’s disease and sleep disorders among others. Read More
University College Cardiff Consultants Ltd. has identified miglustat prodrugs reported to be useful for the treatment of lysosomal storage diseases, Down syndrome and neurodegenerative disorders. Read More
Yeda Research and Development Co. Ltd. has divulged broad-spectrum coronavirus entry inhibitors reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19), SARS-CoV infection and Middle East respiratory syndrome coronavirus (MERS-CoV) infection. Read More
Despite being known for more than 150 years, Duchenne muscular dystrophy (DMD) remains an untreatable disease affecting approximately 1 of every 3,500-5,000 males. Muscles in patients express no or inactive dystrophin, rendering them weak and less mobile. Read More
Shenzhen Zhongge Biotechnology Co. Ltd. has described tyrosine-protein phosphatase non-receptor type 2 (PTPN2; TCPTP) inhibitors reported to be useful for the treatment of cancer, type 2 diabetes, obesity and metabolic diseases. Read More
